{
  "id": 2123914,
  "title": "Johnson & Johnson’s Dividend Looks Well Positioned for the Long Term",
  "url": "https://urgent.news/2026/08/19/johnson-johnsons-dividend-looks-well-positioned-for-the-long-term",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-19T01:31:03.000Z",
  "source": {
    "name": "Yahoo Finance",
    "slug": "yahoo-finance",
    "url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-dividend-looks-well-013103856.html"
  },
  "original_language": "en",
  "account": "Johnson & Johnson (JNJ) remains an attractive dividend stock for investors who prioritize dependable income and a history of growth. In April 2026, the company raised its quarterly dividend by 3.1%, to $1.34, or $5.36 per year, marking its 64th consecutive year of increases. J&J's dividend appears well-supported by its robust earnings base, with $25.3 billion in revenue for the second quarter of 2026 and adjusted EPS of $2.90, a 4.7% increase. Management also raised its full-year outlook, projecting approximately $101.1 billion in sales and adjusted EPS of $11.68. With a payout ratio of roughly 46%, J&J retains more than half of its adjusted earnings, providing room for research and development, acquisitions, debt reduction, and future dividend increases. The company's diverse healthcare portfolio, covering Innovative Medicine and MedTech, mitigates risks from patent expirations and biosimilar competition. Over 75% of sales come from businesses with a No. 1 or No. 2 global market position. J&J's pipeline includes new medicines such as ICOTYDE, which received FDA approval for plaque psoriasis in Q1 2026. Additionally, the company is advancing treatments across oncology, immunology, neuroscience, cardiovascular disease, surgery, and vision. During the pandemic, healthcare needs remain unchanged, offering stability to J&J's dividend. The company's dividend growth is expected to slow but remains steady, supported by strong earnings and free cash flow. J&J's 46% adjusted earnings payout ratio and strong free cash flow provide comfort to investors. While there are challenges, such as biosimilar competition and drug pricing pressure, J&J's financial strength and stability make it a reliable choice for dividend investors seeking long-term growth.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}